Plasmid DNA Manufacturing Market is Anticipated to Witness High Growth Owing to High Demand for Plasmid DNA Manufacturing for Gene Therapy Applications.
Plasmid DNA is extrachromosomal bacterial DNA used in genetic engineering and genetic modification. Plasmid DNA has gained prominence in biopharmaceuticals as genes are being added or modified at the DNA level before being administered to patients. Plasmid DNA is used in gene therapy for treating various diseases including cancer and infectious diseases. It is also finding applications in DNA vaccines. Owing to the growing demand for gene therapy and DNA vaccines, the plasmid DNA manufacturing market is witnessing high growth.
Global plasmid DNA manufacturing market is estimated to be valued at US$ 735.67 million in 2022 and is expected to exhibit a CAGR of 22.5% during the forecast period (2022-2030).
Key Takeaways
Key players operating in the Plasmid DNA manufacturing are Northrop Grumman Corporation, BAE Systems, Lockheed Martin Corporation, Clearpath Robotics Inc., John Bean Technologies Corporation, ECA Group, Israel Aerospace Industries Ltd., Endeavor (Now a part of FLIR system), Harris Corporation, and General Dynamics. These players are focusing on developing innovative manufacturing processes to produce high-quality and high yield of plasmid DNA.
There is a high growth opportunity for Plasmid DNA Manufacturing Market Trends in gene therapy and DNA vaccine production. With rising R&D investments in gene therapy and DNA vaccines, the demand for plasmid DNA is expected to grow significantly over the forecast period. Manufacturers are expected to leverage this opportunity through collaborative partnerships with pharmaceutical companies involved in the development of gene therapies and DNA vaccines.
The global expansion of key players in the plasmid DNA manufacturing market is expected through mergers and acquisitions, partnerships and collaborations, and geographical expansion. Manufacturers are focusing on increasing their geographic presence to cater to the growing global demand. Partnerships with regional CRO/CDMOs/developers provide opportunity for global expansion.
Market Drivers
- Growing demand for gene therapy: Increasing investments and clinical trials in gene therapies for diseases like cancer, infectious diseases, and rare disorders is driving the demand for plasmid DNA which acts as the gene delivery vehicle for these therapies.
- Rise in DNA vaccines: DNA vaccines provide advantages over traditional vaccines and are gaining traction. Growing development of anti-SARS-CoV-2 and other vaccines is propelling the plasmid DNA market growth.
Market Restrains
- Challenges in plasmid DNA production: Large-scale production of high-quality plasmid DNA with high yield and less impurities is a complex process and poses technical and manufacturing challenges. This hampers market growth.
- High production costs: Production costs associated with plasmid DNA manufacturing like fermentation, purification, quality testing etc. are high. This challenges widespread adoption and acts as a restrain.
Segment Analysis
One of the dominating sub segments in the Plasmid DNA Manufacturing Market is the Research and Development segment. It holds the largest share as plasmid DNA finds extensive applications in biomedical research for the production of DNA vaccines and development of gene therapies. Most of the pharmaceutical and biotechnology companies are heavily involved in R&D activities for drug discovery and developing novel therapeutics using plasmid DNA, driving the growth of this sub segment.
The Therapeutics segment is another fast growing sub segment. With the advancements in gene and cell therapy, plasmid DNA is gaining widespread acceptance for the manufacturing of therapeutic products targeting various diseases including cancer. Ongoing clinical trials and new product approvals are augmenting the demand for plasmid DNA in therapeutics.
Global Analysis
On the regional front, North America holds the highest share in the plasmid DNA manufacturing market owing to presence of major players and robust research funding. Availability ofstate-of-the-art facilities and expertise is contributing to the growth of the market in the region.
Meanwhile, the Asia Pacific region is projected to witness the highest growth during the forecast period with increasing investments by international companies looking to tap the opportunities in emerging nations. Growing initiatives by governments to promote local manufacturing are also favouring the regional market expansion. Countries like China and India offer low-cost manufacturing capabilities boosting the plasmid DNA production in Asia Pacific.
For Deeper Insights, Find the Report in the Language that You want:
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)